Geftib 250 mg Tablet

Product Description

Geftib 250 mg Tablet is an effective treatment option for adult patients diagnosed with non-small cell lung cancer (NSCLC) that has metastasized to other areas of the body, particularly in individuals with specific abnormalities in the EGFR gene who have not previously undergone cancer therapy. This targeted therapy works by inhibiting the growth of cancer cells, helping to slow disease progression and improve overall outcomes. It is important to note that Geftib is not recommended for use in children or adolescents due to insufficient data regarding its safety and efficacy in these age groups. Patients should be aware of potential side effects, which may include gastrointestinal issues, skin reactions, and respiratory problems. Regular monitoring by healthcare professionals is crucial to manage any adverse effects effectively. As with any medication, it is essential to discuss your full medical history with your doctor before starting treatment with Geftib 250 mg Tablet. By targeting specific genetic mutations, this medication represents a promising advancement in the management of advanced NSCLC, providing hope for improved survival rates in eligible patients.